report provid clinic updat
loss per share compar estim loss primarili
result higher expect oper expens exceed estim
sg million exceed estim million due higher
estim personnel expens expens million higher
estim million due higher estim collabor payment
quarter cytomx continu make good clinic progress announc
expect present follow-up data part part trial
european societi medic oncolog esmo annual meet octob
outlook revenu unchang modestli
increas estim oper expens increas interest
incom reflect proce recent equiti offer increas share
outstand offer
net effect loss per share increas decreas
expect cytomx earn posit
estim oper expens unchang
increas estim interest reflect higher estim cash balanc
increas estim share outstand
result estim loss per share decreas
estim ep decreas
respect
cytomx announc open expans cohort eight undisclos tumor
type dose part on-going phase i/ii trial
base encourag data monotherapi arm
develop
probodi
platform treatment cancer
platform allow drug select
activ tumor microenviron
remain inert healthi tissu
analyst certif import disclosur see disclosur
cytomx develop probodi proprietari masked-antibodi
technolog treatment cancer compani
cytomx stage develop phase primarili
focu potenti futur revenu valu base
expect cytomx launch first product next
seven year result revenu billion
estim revenu assum success launch
howev case development-stag compani
estim carri high degre risk
pre-clin data continu show probodi abil increas
therapeut index antibodi
immuno-oncolog antibodi therapeut continu show seriou
on-target side effect especi combin
initi data phase studi
launch phase studi
data esmo
ind
partnership agreement other cytomx abl begin
combin studi sooner expect
cytomx clinic program advanc quickli
estim
probodi clinic develop delay
probodi shown increas therapeut index
antibodi futur pre-clin studi
phase studi fail
continu rate cytomx high-qual development-stag platform technolog
compani strong manag team eleg scienc perform anticip
compani launch first drug treatment lymphoma solid tumor
compani cytomx stage develop phase primarili focu
potenti futur revenu valu base expect cytomx launch
first product next seven year estim total revenu grow compound-annual-growth-rate
next eight year increas billion estim
revenu assum success launch howev case development-stag
compani estim nonetheless carri high degre risk
summari believ cytomx stock current trade rang reflect level
risk compani complet phase trial success therefor rate
stock perform
analysi
loss per share compar estim loss primarili
result higher expect oper expens exceed estim
sg million exceed estim million due higher
estim personnel expens expens million higher
estim million due higher estim collabor payment
quarter detail analysi provid exhibit
exhibit analysi compar prior period opco estim
cytomx inc nasdaq- incom statement thousand except per share data estimatedactualactu vs opco bp actuali chang bp actualq chang product relat relat good oper incom incom incom avail common share share per per share dilut compani data oppenheim co estimatesaddit inform avail upon request perform na
cytomx updat prior guidanc expect suffici cash fund
oper
outlook revenu unchang modestli increas
estim oper expens increas interest incom reflect
proce recent equiti offer increas share outstand
offer net effect loss per share increas decreas
expect cytomx earn posit estim
oper expens unchang increas estim
interest reflect higher estim cash balanc increas
estim share outstand result estim loss per share
decreas estim ep
decreas respect detail analysi chang
outlook provid exhibit exhibit
exhibit analysi chang estim sinc last report
cytomx inc nasdaq- incom statement thousand except per share data priorrevisedchang bp priorrevisedchang bp priorrevisedchang bp priorrevisedchang product relat relat good oper incom incom incom avail common share share per per share dilut compani data oppenheim co estimatesaddit inform avail upon request perform na
exhibit analysi chang estim sinc last report
cytomx inc nasdaq-ctmx leah rush cannincom statement oppenheim co thousand except per share bp priorrevisedchang bp priorrevisedchang bp priorrevisedchang product relat relat good oper incom incom incom avail common share share per per share dilut compani data oppenheim co estimatesaddit inform avail upon request cytomx
cytomx announc websit
cytomx announc open expans cohort eight undisclos tumor
type dose part on-going phase i/ii trial
base encourag data monotherapi arm
cytomx announc first subject enrol
phase i/ii dose escal trial treat inform see
note file ind anticip
fda decis file data releas updat
may cytomx announc fda accept ind applic cx-
probodi drug conjug codevelop cytomx
partner achiev mileston trigger million
payment cytomx note file ind
anticip
cytomxclin trialsproduct studyindicationpartner/otherdiscoverylead tumor engag solid tumor w/ nivolumabbristol-my squibbimmunotherapi targetsbristol-my squibbpdcspdcsimmunogenprocar-nkmd probodi bi-specificamgenpre-clinicalproduct candidateindicationdecisionexpect perform na
announc websit
announc websit
june cytomx present result part on-going phase i/ii
studi evalu monotherapi dose-
escal cohort patient advanc heavili pretreat solid tumor
investig conclud earli safeti observ dose-escal
studi combin ipilimumab indic trae rate
trend level report checkpoint inhibitor combin
ipilimumab preliminari result patient demonstr orr
new safeti signal observ note asco data
show single-ag design circul predominantli
intact mask prodrug across dose level
june cytomx present result on-going phase i/ii studi
patient receiv ipilimumab concomit dose schedul
studi part elig patient inhibitor-nav
preliminari conclus behav expect
determin dose mg/kg evalu patient
demonstr orr includ neg express
favor safeti profil note asco data
cytomx announc expect present follow-up data part part
 trial european societi medic oncolog
esmo annual meet octob
cytomx announc expect present initi data accompani
translat scienc program
product candidateindicationfilingexpect candidatestudyindicationexpect time solid tumorsfollow-up data esmo apreliminari data cytomx
provid summari financi outlook full financi
model product detail avail upon request
cytomx inc nasdaq- leah rush cannestim sale earningsoppenheim co million except per share statement product relat growth incom incom share share per per share dilut sheet stockhold statementoper cash flow per cash flow per compani data oppenheim co estimatesaddit inform avail upon request perform na
stock price compani mention report
